OR WAIT 15 SECS
The company will showcase the syriQ BioPure syringe in a 2.25-mL format for autoinjectors at Pharmapack in Paris, France from Feb. 5¬¬–6, 2020.
Schott announced it will showcase the syriQ BioPure syringe in a in a 2.25-mL format for autoinjectors at Pharmapack in Paris, France from Feb. 5ÂÂ–6, 2020. This format is beneficial for administering highly viscous biologics by autoinjector.
“The standard 1-mL long glass syringe is too small in volume for the increase in bioavailability [of biologic drugs], yet a container beyond 3 mL would be too big for administration,” said Anil Kumar Busimi, senior global product manager for the Schott iQ Platform, in the press release. “The new 2.25-mL long syringes therefore ensure the efficiency of the treatment, while also making the administration with an autoinjector easier and more comfortable for the patient.”
According to a company press release, BioPure syringes are manufactured with processes that lower tungsten and adhesive residuals, and the materials are designed for an extractables and leachables profile that ensures drug stability. In addition, accurate dimensions ensure device compatibility.